Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660333 | 1.00 | BACE1 (0.44) | BACE1KDM4ENQO2ALDH1A1TUBB4A | |
| SCHEMBL2973753 | 0.87 | BACE1 (0.49) | BACE1KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL29503803 | 0.84 | LMNA (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL1424822 | 0.84 | LMNA (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL31543090 | 0.84 | HSD11B1 (0.40) | KDM4EALDH1A1CYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL22939573 | 0.83 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL29660408 | 0.83 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL30363911 | 0.82 | LMNA (0.50) | KDM4ENQO2ALDH1A1HPGDCA1 | |
| SCHEMBL11904948 | 0.82 | LMNA (0.50) | KDM4ENQO2ALDH1A1HPGDCA1 | |
| SCHEMBL245102 | 0.81 | MAPK1 (0.46) | KDM4ENQO2ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| CN-115697985-B | CD38 inhibitors | 米托布里奇公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024258897-A1 | ALKOXYPYRIDINYL AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | DEM BIOPHARMA, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230382901-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | NAPA THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| CN-117062813-A | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116710090-A | Heteroaryl amide inhibitors of CD38 | NAPA医疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-6610853-B1 | N-(phenylsulfonyl)picolinamide derivatives, process for producing the same, and herbicide | KUREHA KAGAKU KOGYO K.K. (JP) | 2003-08-26 | — | — | US | disclosed |
| EP-1069112-A1 | N-(PHENYLSULFONYL) PICOLINAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | BACE1 3690/4885KDM4E 428/4885NQO2 446/4885 |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | BACE1 3316/4885KDM4E 1448/4885NQO2 245/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | BACE1 3316/4885KDM4E 1448/4885NQO2 245/4885 |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | BACE1 3316/4885KDM4E 1448/4885NQO2 245/4885 |
| US-20230382901-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | CD38, CD22, PARP12 | BACE1 1673/4885KDM4E 2275/4885NQO2 29/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | BACE1 2158/4885KDM4E 2756/4885NQO2 512/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | BACE1 505/4885KDM4E 40/4885NQO2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.